Shots: Kite will receive a one-time upfront to purchase Kite’s individualized solid tumor neoantigen TCR discovery platform, R&D & clinical manufacturing facility in Gaithersburg. The Transaction is expected to be close at the end of Jul’21 BioNTech will use the Kite’s facility to support clinical trials in the US & will add its cell therapy …
Novavax reported that its Covid-19 vaccine was 100% effective at protecting against moderate and severe disease and 90.4% effective overall. The vaccine is seen as an important alternative to messenger RNA vaccines because of its storage and distribution advantages.
Novavax says it’s building up its manufacturing capacity now to be ready to ship Covid-19 vaccine globally as emergency authorizations are granted in coming months. The company expects to seek FDA authorization in the second quarter.
The company is running a Phase I/II study that started in May in Australia and plans to open a Phase III study of its vaccine candidate, NVX-CoV2373, that will enroll up to 30,000 participants starting in the fall.